Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.82B |
$80.97
+3.71%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.82B |
$15.49
-0.03%
|
|
INVA
Innoviva, Inc.
Zoliflodacin is an oral small-molecule therapeutic in Innoviva's pipeline, representing the IST focus on oral antibiotics.
|
$1.81B |
$24.24
+2.71%
|
|
SGRY
Surgery Partners, Inc.
Operates outpatient surgery centers and ASCs, the core service offering and revenue driver.
|
$1.81B |
$14.00
+4.24%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.80B |
$35.69
+5.69%
|
|
NRIX
Nurix Therapeutics, Inc.
Nurix's pipeline is oncology-focused with BTK/BRAF degraders and IRAK4 degrader in collaboration, aligning with Biotech - Oncology.
|
$1.80B |
$17.50
+4.88%
|
|
AORT
Artivion, Inc.
Artivion's core business is manufacturing medical devices and implantable tissues across cardiology and vascular platforms.
|
$1.79B |
$37.72
+2.65%
|
|
AXGN
AxoGen, Inc.
Axogen's Avance Nerve Graft and Axoguard nerve-repair products are surgical devices used in peripheral nerve repair.
|
$1.78B |
$38.50
+3.02%
|
|
TSHA
Taysha Gene Therapies, Inc.
TSHA-102 is an AAV9-based gene therapy product directly developed by Taysha for Rett syndrome.
|
$1.76B |
$6.42
+7.98%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$1.75B |
$5.07
+5.41%
|
|
ADUS
Addus HomeCare Corporation
Core service line providing Home Health & Hospice care in-home.
|
$1.74B |
$94.41
+1.16%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$1.73B |
$14.95
+5.54%
|
|
HRMY
Harmony Biosciences Holdings, Inc.
Harmony's WAKIX and pipeline assets target rare neurological diseases, aligning with Biotech - Rare Diseases.
|
$1.73B |
$29.98
+1.92%
|
|
NKTR
Nektar Therapeutics
NKTR's core immunology focus with REZPEG and TNFR2 antibody programs aligns with Immunology Therapeutics.
|
$1.73B |
$84.84
+1.01%
|
|
OMCL
Omnicell, Inc.
XT Series automated dispensing systems, XR2 robot, IVX compounding robot are medical devices and biometrics products.
|
$1.72B |
$38.29
+1.84%
|
|
AHCO
AdaptHealth Corp.
Direct provider of Home Health & Hospice services and in-home patient care.
|
$1.71B |
$12.65
+0.56%
|
|
BBAI
BigBear.ai Holdings, Inc.
VeriScan biometric traveler processing indicates biometrics/biometric sensing offerings.
|
$1.68B |
$3.85
+2.80%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$1.67B |
$57.60
+2.04%
|
|
ATEC
Alphatec Holdings, Inc.
Alphatec's primary business is spine/orthopedic implants and devices.
|
$1.65B |
$11.11
+2.68%
|
|
NBTX
Nanobiotix S.A.
NBTXR3 is Nanobiotix's lead oncology therapy (hafnium oxide nanoparticle) used to enhance radiation therapy, fitting Biotech - Oncology.
|
$1.63B |
$34.07
+4.96%
|
|
PRGO
Perrigo Company plc
Digestive Health OTC products are a significant Perrigo self-care category.
|
$1.62B |
$11.79
+3.24%
|
|
CTS
CTS Corporation
CTS targets medical end-markets with diagnostic/sensor applications; tagged under Medical Devices & Biometrics.
|
$1.60B |
$55.20
+1.13%
|
|
IMCR
Immunocore Holdings plc
KIMMTRAK is an oncology immunotherapy (melanoma) core product; Immunocore's pipeline expands the platform into oncology.
|
$1.59B |
$31.41
+0.10%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor's lead asset deramiocel is a cell-based therapy, the core product offering of the company.
|
$1.59B |
$34.70
+0.32%
|
|
PLSE
Pulse Biosciences, Inc.
Pulse Biosciences develops nsPFA-based medical devices (e.g., CellFX platform) for non-thermal tissue ablation across soft tissue and cardiac indications.
|
$1.59B |
$23.37
+13.94%
|
|
ENOV
Enovis Corporation
Directly produces orthopedic devices and implants used in reconstructive surgery.
|
$1.58B |
$27.93
+0.94%
|
|
ARDX
Ardelyx, Inc.
Ardelyx's core offerings are oral, small-molecule therapeutics (IBSRELA and XPHOZAH) based on tenapanor.
|
$1.57B |
$6.44
+2.55%
|
|
PGNY
Progyny, Inc.
Progyny Rx is an integrated pharmacy benefits solution, aligning with PBM-like capabilities for medications within its program.
|
$1.56B |
$18.12
+1.09%
|
|
UFPT
UFP Technologies, Inc.
Design and manufacture of customized components and subsystems used in medical devices (foams, films, plastics, fabrics, die-cut parts, and assembly).
|
$1.56B |
$202.37
+4.29%
|
|
HROW
Harrow Health, Inc.
Direct ophthalmic drug products (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) are core branded ophthalmic pharmaceuticals.
|
$1.54B |
$41.52
+2.14%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$1.53B |
$27.49
+0.44%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$1.53B |
$3.85
+1.45%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX targets rare endocrine/metabolic disorders (e.g., chronic hypoparathyroidism), aligning with Rare Diseases biotech focus.
|
$1.52B |
$33.77
+1.66%
|
Showing page 12 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
